Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

AMAG Pharmaceuticals, Inc. to Host Conference Call on July 29, 2008 to Discuss Financial Results for the Quarter Ended June 30, 2008

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended June 30, 2008 before the U.S. financial markets open on Tuesday, July 29, 2008. The announcement will be followed by a conference call at 8:30 a.m. ET during which management will discuss the Companys financial results, business highlights and its development programs.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (706) 902-1303 for international access. A telephone replay will be available from approximately 10:00 a.m. ET on July 29, 2008 through midnight July 31, 2008. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and replay is 56344417.

An audio webcast of the call will be available through the Investors section of the Companys website at www.amagpharma.com. The webcast replay will be available from approximately 10:00 a.m. ET on July 29, 2008 through midnight August 29, 2008.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Companys key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease. The Company submitted a New Drug Application for marketing approval of ferumoxytol as an intravenous iron replacement therapy in chronic kidney disease patients with the FDA in December 2007, which was accepted for filing by the FDA in February 2008.

Contacts:

AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362
kgalfetti@amagpharma.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.